Department of Health and Human Services
200 Independence Avenue, S.W.
Washington
D.C.
20201
United States
Tel: 877-696-6775
Website: http://www.hhs.gov/
Email: hhsmail@os.dhhs.gov
104 articles with Department of Health and Human Services
-
GeoVax Issues Open Letter to HHS Secretary Alex Azar
2/14/2019
GeoVax Labs, Inc., a biotechnology company developing human vaccines, today published an open letter to U.S. Department of Health and Human Services Secretary Alex Azar in response to the HHS initiative “Ending the HIV Epidemic: A Plan for America.”
-
After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the pro...
-
Last week HHS floated a plan that would allow companies to pass rebates of 26 to 30 percent of a drug’s list price directly to patients in order to be reflected in what consumers pay at the pharmacy counter.
-
Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
-
The plan is aimed at providing new transparency to the prescription drug market and removing the veil of hidden rebates conducted between companies and pharmacy benefits managers.
-
The U.S. Senate Finance Committee and the House Oversight Committee started hearings on Tuesday, January 29, focused on dealing with high drug prices.
-
U.S. federal lawmakers are discussing various legislative plans that could lower the out-of-pocket expenses many Americans pay for their medications. The plans are coming from both chambers of Congress and with a divided government, lines in the sand will likely be drawn.
-
In theory, the U.S. Food and Drug Administration (FDA) is tasked with overseeing the safety of food and drugs in the U.S. based on science, not politics. That doesn’t always work.
-
In a December 17, Washington Post op-ed, Senator Elizabeth Warren (D-MA), proposed The Affordable Drug Manufacturing Act, which would allow the Department of Health and Human Services (HHS) to manufacture or contract out the manufacture of generic drugs.
-
7 Biotech Trends to Look Out for in 2019
12/26/2018
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle. -
The FDA has been looking for ways to increase access to naloxone, an opioid overdose reversal drug, and the new guidelines are part of that effort.
-
NCLA: Proposed 'Drug Pricing Rule' Gives Centers for Medicare and Medicaid Services Unwarranted Authority
12/18/2018
NCLA Submits Comment to HHS and CMS Critical of Rulemaking
-
Lawsuit Charges FDA, NIH With Failing to Follow Established Law for Reporting of Clinical Trial Data
12/12/2018
The lawsuit alleges that the government is letting a number of researchers off the hook of reporting clinical data. -
Leading Scientists Strongly Reject FDA 8-Factor Analysis Of Kratom, Call Upon The DEA And NIDA To Reexamine FDA Claims
11/28/2018
American Kratom Association Requests FDA to Retract Kratom Scheduling Recommendation
-
The Garden State joins a long list of governments that have brought charges against opioid makers during an addiction crisis that claims the lives of 116 Americans per day.
-
Response to HHS Secretary Azar's comments on a radiation oncology alternative payment model
11/8/2018
Following comments today from Alex Azar, the Secretary of Health and Human Services, on an alternative payment model for radiation oncology, the American Society for Radiation Oncology (ASTRO) issued the following statement from CEO Laura Thevenot
-
Scott Gottlieb, commissioner of the Food and Drug Administration (FDA) is notoriously outspoken. Let’s take a look at some of Gottlieb’s more recent statements.
-
As part of a plan to lower prescription drug prices for millions of Americans, President Donald Trump is set to announce a sweeping plan to overhaul how Medicare pays for medication.
-
The FDA, as well as other government agencies, have expressed alarm at the rate of opioid-related overdoses in the United States – an issue that has become an epidemic across the heartland.
-
The Senate passed the bill on October 3 in a 98 to 1 vote. The House passed its version a week earlier in a vote of 393 to 8. The legislation includes provisions to promote research into new pain management drugs and expands access to substance abuse treatment for Medicaid patients.